Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers.

A survey of patients with advanced cancer treated by biologic response modifiers (BRMs), including (i) recombinant interleukin-2 and lymphokine-activated killer cells, (ii) recombinant interleukin-2 and alpha interferon, and (iii) tumor necrosis factor, was done. A total of 52 patients were reviewed...

Celý popis

Podrobná bibliografie

Vydáno v:	J Clin Microbiol
Hlavní autoři:	Maoleekoonpairoj, S, Mittelman, A, Savona, S, Ahmed, T, Puccio, C, Gafney, E, Skelos, A, Arnold, P, Coombe, N, Baskind, P
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Microbiology (ASM) 1989
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC267014/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2584381/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jcm.27.10.2305-2308.1989
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!